Aclaris Therapeutics (ACRS) Competitors $1.82 +0.01 (+0.55%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$1.80 -0.02 (-1.10%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. NRIX, NAGE, PHAR, AVBP, SANA, GYRE, OCS, DNA, ATAI, and IMTXShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Nurix Therapeutics Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks atai Life Sciences Immatics Aclaris Therapeutics (NASDAQ:ACRS) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Which has preferable valuation & earnings, ACRS or NRIX? Aclaris Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$16.79M11.74-$132.07M-$1.37-1.33Nurix Therapeutics$54.55M13.38-$193.57M-$2.61-3.66 Does the media prefer ACRS or NRIX? In the previous week, Nurix Therapeutics had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 9 mentions for Nurix Therapeutics and 4 mentions for Aclaris Therapeutics. Nurix Therapeutics' average media sentiment score of 1.31 beat Aclaris Therapeutics' score of 0.81 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ACRS or NRIX? 98.3% of Aclaris Therapeutics shares are held by institutional investors. 5.6% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer ACRS or NRIX? Aclaris Therapeutics presently has a consensus target price of $8.71, suggesting a potential upside of 378.81%. Nurix Therapeutics has a consensus target price of $28.87, suggesting a potential upside of 202.27%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 Is ACRS or NRIX more profitable? Nurix Therapeutics has a net margin of -234.57% compared to Aclaris Therapeutics' net margin of -802.03%. Aclaris Therapeutics' return on equity of -34.01% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-802.03% -34.01% -24.18% Nurix Therapeutics -234.57%-45.26%-34.71% Which has more risk & volatility, ACRS or NRIX? Aclaris Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. SummaryAclaris Therapeutics and Nurix Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.16M$2.80B$5.79B$9.78BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-1.3322.5330.8326.37Price / Sales11.74729.40460.97120.29Price / CashN/A177.7737.7659.36Price / Book1.496.2910.186.62Net Income-$132.07M$32.94M$3.26B$265.42M7 Day Performance4.00%1.13%2.79%3.08%1 Month Performance8.33%1.52%3.95%0.77%1 Year Performance51.67%11.43%44.12%22.97% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.6649 of 5 stars$1.82+0.6%$8.71+378.8%+52.9%$197.16M$16.79M-1.33100NRIXNurix Therapeutics2.7995 of 5 stars$10.20-3.6%$28.87+183.0%-61.2%$808.83M$54.55M-3.91300News CoveragePositive NewsAnalyst UpgradeHigh Trading VolumeNAGENiagen Bioscience1.1755 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.12M$99.60M48.19120PHARPharming Group2.3774 of 5 stars$12.39+6.4%$30.00+142.1%+72.0%$798.20M$297.20M-95.31280Positive NewsGap UpAVBPArriVent BioPharma2.4495 of 5 stars$19.24-1.5%$39.14+103.4%-30.7%$792.31MN/A-4.7940News CoverageAnalyst UpgradeAnalyst RevisionSANASana Biotechnology3.2092 of 5 stars$3.40+2.1%$8.00+135.3%-41.7%$791.90MN/A-3.21380GYREGyre Therapeutics1.2151 of 5 stars$7.85-3.6%N/A-34.5%$783.99M$105.76M785.7940News CoverageAnalyst ForecastAnalyst RevisionOCSOculis2.9609 of 5 stars$18.06+0.9%$35.33+95.6%+45.5%$781.56M$780K-6.842News CoverageEarnings ReportAnalyst ForecastDNAGinkgo Bioworks1.0285 of 5 stars$13.79+4.6%$8.50-38.4%+64.8%$780.25M$227.04M-2.35640Analyst ForecastATAIatai Life Sciences3.6032 of 5 stars$4.05+4.4%$11.25+177.8%+257.0%$777.31M$310K-5.8780Gap UpIMTXImmatics2.1592 of 5 stars$6.21-1.9%$14.67+136.2%-50.6%$769.41M$168.65M-9.55260High Trading Volume Related Companies and Tools Related Companies Nurix Therapeutics Competitors Niagen Bioscience Competitors Pharming Group Competitors ArriVent BioPharma Competitors Sana Biotechnology Competitors Gyre Therapeutics Competitors Oculis Competitors Ginkgo Bioworks Competitors atai Life Sciences Competitors Immatics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access